<DOC>
	<DOCNO>NCT01929811</DOCNO>
	<brief_summary>To evaluate docetaxel , epirubicin cyclophosphomide ( TEC ) TEC plus metformin neoadjuvant treatment breast cancer patient . The aim evaluate whether metformin increase pCR rate combination TEC regimen neoadjuvant setting .</brief_summary>
	<brief_title>NeoMET Study Neoadjuvant Treatment Breast Cancer</brief_title>
	<detailed_description>Neoadjuvant therapy standard treatment locally advance breast cancer adopt early breast cancer treatment . A meta-analysis show difference neoadjuvant therapy adjuvant therapy term survival overall disease progression . Therefore , neoadjuvant treatment offer standard treatment alternative adjuvant treatment patient expect candidate adjuvant systemic chemotherapy . Patients achieve pCR treatment superior outcome . The taxanes introduce clinical practice early 1990s , recent meta-analysis show compare anthracycline-containing chemotherapy , taxanes-containing regimen significantly reduce annual breast cancer recurrences death . Right , TAC regimen widely accept adjuvant neoadjuvant chemotherapy regimen breast cancer treatment . Metformin , inexpensive oral agent commonly use treat type 2 diabetes , garner increase attention potential anti-cancer agent . In neoadjuvant treatment breast cancer , retrospective clinical study MDACC report significantly increase pCR rate standard neoadjuvant chemotherapy diabetic breast cancer patient receive metformin ( 24 % pCR ) compare diabetic receive metformin ( 8 % pCR ) , intermediate rate non-diabetics receive metformin ( 16 % pCR ) , indicate metformin may increase pCR rate neoadjuvant chemotherapy . Base data , initiate prospective study evaluate docetaxel , epirubicin cyclophosphomide ( TEC ) TEC plus metformin neoadjuvant treatment breast cancer patient . Our aim evaluate whether metformin increase pCR rate combination TEC regimen neoadjuvant setting .</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>woman age ≥18 year &lt; 70 year life expectancy &gt; 12 month Measurable disease breast axillary lymph node , histologically confirm invasive breast cancer core needle biopsy , T≥2cm stage IIb stage III accord AJCC classification , fineneedle aspiration encourage every patient metastasis suspicious node ; Biopsy specimens available ER , PgR , Her2 proliferation biomarker detection ; Adequate bone marrow function : Neutrophil ≥ 1.5*109/L ; Hb ≥ 100g/L ; PLT ≥ 80*109/L ; Adequate liver renal function : Serum AST ≤ 90U/L Bilirubin ≤ upper limit normal ( UNL ) range Serum creatinine ≤110 umol/L，calculated creatinine clearance ≥ 60 mL/min ; BUN ≤ 7.1mmol/L ; Has ECOG Performance Score 01 ; BMI ≥ 25kg/m2 hyperglycemia hyperlipemia hypertension ; Willing take biopsy neoadjuvant chemotherapy patient must accessible treatment followup ; Women potential childbearing must negative pregnancy test ( urine serum ) within 7 day drug administration agree use acceptable method birth control avoid pregnancy duration study ; Written inform consent accord local ethic committee requirement . Prior systemic locoregional treatment breast cancer , include chemotherapy ; Metastatic breast cancer ; With history malignant tumor except uterine cervix cancer situ skin basal cell carcinoma ; Patients medical condition indicate intolerant neoadjuvant therapy relate treatment , include uncontrolled pulmonary disease , severe infection , active peptic ulcer , coagulation disorder , connective tissue disease myelosuppressive disease ; Has active hepatitis B hepatitis C abnormal liver function test ( LFTs ) know HIV positive ; Contraindication use dexamethasone , chemotherapy agent metformin ; History congestive heart failure , uncontrolled symptomatic angina pectoris , arrhythmia myocardial infarction ; poorly control hypertension ( systolic BP &gt; 180mmHg diastolic BP &gt; 100mmHg ) ; Has peripheral neuropathy ≥ grade 1 ; Patient pregnant breast feeding ( willing stop breast feeding ) ; Not willing take core needle biopsy patient psychiatric disorder disease lead incompliance therapy Known severe hypersensitivity drug study ; Treatment investigational drug within 30 day begin study treatment . History lactic metabolic acidosis Consumption &gt; 3 alcoholic beverage per day ( average )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>